Brandon Capital Partners, a Melbourne, Australia–based venture capital firm that specializes in biotechnology and pharmaceutical investments, has selected DealCloud to help with company tracking, deal tracking, and pipeline management.
“DealCloud offered the comprehensive and user-friendly deal tracking capability we were in search of,” said Amy Perkin, Chief Financial Officer at Brandon Capital. “Keeping track of investment opportunities and ensuring we follow up efficiently is critical to our success. As we grew, so did the number of deals in our pipeline and the size of the team, making deal tracking more complicated. DealCloud enables us to visualize and prioritize the pipeline in real time.”
Brandon Capital invests in promising biomedical opportunities that have the potential to improve patients’ lives. From early-stage seed investment and expansion capital to proof-of-concept and commercialization, the firm supports life science companies through all phases of their journeys.
Brandon Capital partners with entrepreneurs for the long haul, working collaboratively to support the development and commercialization of their technology, thereby creating value for their teams, investors, and — ultimately — patients. The team at Brandon Capital seeks to invest early and has been the founding investor for most of the 30 companies within the firm’s current portfolio.
“We’re very impressed by the investments Brandon Capital has made in the biomedical space, and supporting the firm’s team with deal tracking and pipeline management is very rewarding,” said Amit Lalwani, Head of Global Business Development at DealCloud. “We’re poised to support more venture capital firms like Brandon Capital in 2021 and for many years to come.”
DealCloud, an Intapp company, provides a single-source deal, relationship, and firm management platform that enables firms to power their dealmaking process from strategy to origination to execution. We offer fully configurable solutions purpose-built for the complex relationships and structures of private equity and growth capital firms, investment banks, private and publicly traded companies, debt capital providers, and other investors. For more information, visit dealcloud.com.
About Brandon Capital Partners
Brandon Capital Partners is a venture capital firm that manages the Medical Research Commercialisation Fund (MRCF), Australia’s and New Zealand’s largest life science investment fund. The MRCF is a unique collaboration between major Australian pension funds, the Australian and New Zealand governments, Australian state governments, and more than 50 leading medical research institutes and research hospitals. The MRCF supports the development and commercialization of early-stage biomedical discoveries associated with member organizations, providing both capital and expertise to guide the successful development of new therapies. Brandon Capital currently has more than 800 million Australian dollars under management and maintains offices in Melbourne and Sydney as well as Palo Alto, California. For more information about Brandon Capital and the MRCF, visit brandoncapital.com.au and mrcf.com.au.